OVID
Ovid Therapeutics Inc.
There isn't enough reported data to score OVID yet.
OVID Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Strong |
OVID's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OVID PE Valuation
OVID has no meaningful PE right now: it lost money over the past year.
OVID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect OVID's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OVID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.16 | +$0.33 |
| Q2 2026 | -$0.23 | +$0.29 |
| Q1 2026 | -$0.21 | +$0.13 |
| Q4 2025 | -$0.23 | +$0.14 |
| Q3 2025 | -$0.49 | -$0.03 |
| Q2 2025 | -$0.52 | -$0.10 |
| Q1 2025 | -$0.34 | +$0.38 |
| Q4 2024 | -$0.37 | +$0.37 |
OVID is still losing money, but far less than before: $0.16 per share over the past year, against $1.46 at its worst in mid-2020.
OVID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $733K | -88% |
| Q4 2025 | $718K | +845% |
| Q3 2025 | $132K | -24% |
| Q2 2025 | $6.3M | +3611% |
| Q1 2025 | $130K | -12% |
| Q4 2024 | $76K | -46% |
| Q3 2024 | $173K | +59% |
| Q2 2024 | $169K | +125% |
OVID's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2142% | -2061 points |
| Q4 2025 | -1712% | +12396 points |
| Q3 2025 | -9487% | -1842 points |
| Q2 2025 | -81% | +12059 points |
| Q1 2025 | -9654% | +2114 points |
| Q4 2024 | -14108% | -1260 points |
| Q3 2024 | -7645% | +3393 points |
| Q2 2024 | -12140% | +6756 points |
OVID's operating margin was −2142% last quarter, up 7512 points from the same quarter a year ago.
OVID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.9M | -$3M |
| Q2 2026 | -$17.6M | -$12.8M |
| Q1 2026 | -$13.9M | -$3.6M |
| Q4 2025 | -$10.4M | -$378K |
| Q3 2025 | -$12.9M | +$2.1M |
| Q2 2025 | -$4.8M | +$9.5M |
| Q1 2025 | -$10.3M | +$6.4M |
| Q4 2024 | -$10M | +$1.9M |
OVID has burned cash in almost every quarter: −$58M over the past year, against −$38M the year before.
OVID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.4% | -6.6M shares |
| 1 year | +165% | +118M shares |
| 3 years | +167% | +118M shares |
| 5 years | +178% | +121M shares |
| Available history | +245% | +134M shares |
OVID has 189M diluted shares, up 165% from a year ago.
OVID Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | -1.5x | Net Cash |
| Q3 2021 | -1.6x | Net Cash |
| Q2 2021 | -1.7x | Net Cash |
| Q1 2021 | -2.0x | Net Cash |
OVID has more cash than debt.
OVID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.0 | Neutral |
| Stochastic | 62.2 | Neutral |
OVID's weekly RSI is 52 (neutral) and its Stochastic is 62 (neutral).
OVID PE vs Healthcare Sector
OVID has no meaningful PE right now: it lost money over the past year.
OVID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.44 | 4.5% above |
| 20 week MA | $2.55 | 0% above |
| 50 week MA | $2.28 | 12% above |
| 100 week MA | $1.53 | 67% above |
| 200 week MA | $2.11 | 21% above |
OVID's trend is mixed: it's above four of its five weekly moving averages, and 21% above its 200-week average.
OVID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.61 | $2.61 | -43% |
| 2021 | $2.61 | $3.39 | +30% |
| 2022 | $3.39 | $1.70 | -50% |
| 2023 | $1.70 | $3.22 | +89% |
| 2024 | $3.22 | $0.97 | -70% |
| 2025 | $0.97 | $1.78 | +84% |
| 2026 YTD | $1.78 | $2.55 | +43% |
OVID is up 43% so far in 2026, after finishing lower in three of the previous six years.